243
Participants
Start Date
November 30, 2014
Primary Completion Date
October 31, 2016
Study Completion Date
October 31, 2016
Sarilumab SAR153191 (REGN88)
Pharmaceutical form: solution for injection Route of administration: subcutaneous
Placebo (for sarilumab)
Pharmaceutical form: solution for injection Route of administration: subcutaneous
Methotrexate
Dispensed according to local practice.
Folic acid
Dispensed according to local practice.
Investigational Site Number 392010, Asahi-Shi
Investigational Site Number 392001, Asahikawa-Shi
Investigational Site Number 392035, Asahikawa-Shi
Investigational Site Number 392070, Beppu-Shi
Investigational Site Number 392036, Chiba
Investigational Site Number 392083, Chūōku
Investigational Site Number 392047, Fuchu-Shi
Investigational Site Number 392004, Fukui-shi
Investigational Site Number 392007, Fukuoka
Investigational Site Number 392038, Fukuoka
Investigational Site Number 392039, Fukuoka
Investigational Site Number 392078, Fukushima
Investigational Site Number 392054, Funabashi-Shi
Investigational Site Number 392015, Hachioji-Shi
Investigational Site Number 392085, Hannan-Shi
Investigational Site Number 392091, Hiroshima
Investigational Site Number 392098, Hiroshima
Investigational Site Number 392009, Hitachi-Naka
Investigational Site Number 392011, Hitachi-Naka
Investigational Site Number 392030, Ichinomiya-Shi
Investigational Site Number 392002, Iizuka-Shi
Investigational Site Number 392019, Kagoshima
Investigational Site Number 392066, Kamakura-Shi
Investigational Site Number 392086, Kamogawa-Shi
Investigational Site Number 392050, Kato-Shi
Investigational Site Number 392037, Kawachi-Nagano-Shi
Investigational Site Number 392093, Kawagoe-Shi
Investigational Site Number 392099, Kawasaki-Shi
Investigational Site Number 392016, Kirishima-Shi
Investigational Site Number 392013, Kitakyushu-Shi
Investigational Site Number 392024, Kitakyushu-Shi
Investigational Site Number 392045, Kitakyushu-Shi
Investigational Site Number 392063, Kiyose-Shi
Investigational Site Number 392051, Kobe
Investigational Site Number 392097, Kochi
Investigational Site Number 392040, Koushi-Shi
Investigational Site Number 392069, Kumamoto
Investigational Site Number 392089, Kurashiki-Shi
Investigational Site Number 392065, Kushiro
Investigational Site Number 392026, Matsuyama
Investigational Site Number 392081, Matsuyama
Investigational Site Number 392094, Matsuyama
Investigational Site Number 392042, Meguro-Ku
Investigational Site Number 392082, Meguro-Ku
Investigational Site Number 392012, Mito
Investigational Site Number 392034, Miyagi-Gun
Investigational Site Number 392053, Morioka
Investigational Site Number 392032, Nagano
Investigational Site Number 392064, Nagasaki
Investigational Site Number 392043, Nagoya
Investigational Site Number 392056, Nagoya
Investigational Site Number 392076, Nagoya
Investigational Site Number 392080, Nagoya
Investigational Site Number 392031, Nakano
Investigational Site Number 392046, Narashino-Shi
Investigational Site Number 392067, Narashino-Shi
Investigational Site Number 392044, Nishinomiya-Shi
Investigational Site Number 392062, Okayama
Investigational Site Number 392008, Omura-Shi
Investigational Site Number 392057, Osaka
Investigational Site Number 392060, Osaka
Investigational Site Number 392061, Osaka
Investigational Site Number 392096, Osaka
Investigational Site Number 392027, Osaki-Shi
Investigational Site Number 392059, Ōita
Investigational Site Number 392049, Sagamihara-Shi
Investigational Site Number 392072, Saitama-Shi
Investigational Site Number 392075, Sakaishi
Investigational Site Number 392014, Sapporo
Investigational Site Number 392068, Sapporo
Investigational Site Number 392073, Sapporo
Investigational Site Number 392006, Sasebo-Shi
Investigational Site Number 392021, Sendai
Investigational Site Number 392022, Sendai
Investigational Site Number 392033, Sendai
Investigational Site Number 392071, Sendai
Investigational Site Number 392100, Sendai
Investigational Site Number 392029, Shizuoka
Investigational Site Number 392025, Sumida-Ku
Investigational Site Number 392092, Sumida-Ku
Investigational Site Number 392023, Takaoka-Shi
Investigational Site Number 392095, Takarazuka-Shi
Investigational Site Number 392020, Takasaki-Shi
Investigational Site Number 392088, Takatsuki-Shi
Investigational Site Number 392018, Tokorozawa-Shi
Investigational Site Number 392003, Tomakomai-Shi
Investigational Site Number 392005, Tomakomai-Shi
Investigational Site Number 392077, Tonami-Shi
Investigational Site Number 392052, Toshima-Ku
Investigational Site Number 392058, Toyama
Investigational Site Number 392055, Toyonaka-Shi
Investigational Site Number 392074, Urasoe-Shi
Investigational Site Number 392079, Urayasu-Shi
Investigational Site Number 392048, Yokohama
Investigational Site Number 392090, Yokohama
Investigational Site Number 392101, Yokohama
Lead Sponsor
Regeneron Pharmaceuticals
INDUSTRY
Sanofi
INDUSTRY